RU2004132847A - Способ лечения гиперсекреции слизи - Google Patents
Способ лечения гиперсекреции слизи Download PDFInfo
- Publication number
- RU2004132847A RU2004132847A RU2004132847/15A RU2004132847A RU2004132847A RU 2004132847 A RU2004132847 A RU 2004132847A RU 2004132847/15 A RU2004132847/15 A RU 2004132847/15A RU 2004132847 A RU2004132847 A RU 2004132847A RU 2004132847 A RU2004132847 A RU 2004132847A
- Authority
- RU
- Russia
- Prior art keywords
- groups
- alkyl
- group
- optionally
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02007699.8 | 2002-04-05 | ||
| EP02007699 | 2002-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004132847A true RU2004132847A (ru) | 2006-08-20 |
Family
ID=28685842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004132847/15A RU2004132847A (ru) | 2002-04-05 | 2003-04-02 | Способ лечения гиперсекреции слизи |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1494645A2 (enExample) |
| JP (1) | JP2005528374A (enExample) |
| KR (1) | KR20040101398A (enExample) |
| CN (1) | CN1658834A (enExample) |
| AU (1) | AU2003224025A1 (enExample) |
| BR (1) | BR0309009A (enExample) |
| CA (1) | CA2479520A1 (enExample) |
| IL (1) | IL163737A0 (enExample) |
| MX (1) | MXPA04009605A (enExample) |
| NZ (1) | NZ536278A (enExample) |
| PL (1) | PL372963A1 (enExample) |
| RU (1) | RU2004132847A (enExample) |
| WO (1) | WO2003084503A2 (enExample) |
| ZA (1) | ZA200406910B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070010529A1 (en) * | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| WO2006137421A1 (ja) * | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 局所投与剤 |
| FR2903774B1 (fr) * | 2006-07-17 | 2008-09-05 | Renault Sas | Procede de validation d'un diagnostic de fontionnement d'un dispositif. |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| KR20110070887A (ko) | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | Ｐ38 엠에이피 키나제 억제제 |
| KR20110094127A (ko) | 2008-12-11 | 2011-08-19 | 레스피버트 리미티드 | Ｐ38 ｍａｐ 키나제 억제제 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3078232A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of dux4 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| HUP0202248A3 (en) * | 1999-03-12 | 2006-06-28 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| MXPA01011976A (es) * | 1999-05-21 | 2002-05-06 | Scios Inc | Derivados de tipo indol como inhibidores de cinasa p38. |
| WO2001012609A1 (en) * | 1999-08-19 | 2001-02-22 | Signal Pharmaceuticals, Inc. | Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| HUP0204333A3 (en) * | 1999-09-17 | 2004-07-28 | Smithkline Beecham Corp | Use of csaids in rhinovirus infection |
| WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP2004511542A (ja) * | 2000-10-19 | 2004-04-15 | スミスクライン・ビーチャム・コーポレイション | 煙の吸入の治療のためのｐ３８阻害剤の使用 |
| CA2490819A1 (en) * | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| CA2466665A1 (en) * | 2001-11-09 | 2003-05-22 | Scios Inc. | Method to treat cystic fibrosis |
-
2003
- 2003-04-02 BR BR0309009-4A patent/BR0309009A/pt not_active IP Right Cessation
- 2003-04-02 AU AU2003224025A patent/AU2003224025A1/en not_active Abandoned
- 2003-04-02 RU RU2004132847/15A patent/RU2004132847A/ru not_active Application Discontinuation
- 2003-04-02 CA CA002479520A patent/CA2479520A1/en not_active Abandoned
- 2003-04-02 EP EP03720407A patent/EP1494645A2/en not_active Ceased
- 2003-04-02 KR KR10-2004-7015891A patent/KR20040101398A/ko not_active Withdrawn
- 2003-04-02 NZ NZ536278A patent/NZ536278A/en unknown
- 2003-04-02 CN CN038129884A patent/CN1658834A/zh active Pending
- 2003-04-02 IL IL16373703A patent/IL163737A0/xx unknown
- 2003-04-02 JP JP2003581743A patent/JP2005528374A/ja active Pending
- 2003-04-02 MX MXPA04009605A patent/MXPA04009605A/es unknown
- 2003-04-02 PL PL03372963A patent/PL372963A1/xx not_active Application Discontinuation
- 2003-04-02 WO PCT/EP2003/003434 patent/WO2003084503A2/en not_active Ceased
-
2004
- 2004-08-31 ZA ZA200406910A patent/ZA200406910B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ536278A (en) | 2007-05-31 |
| AU2003224025A1 (en) | 2003-10-20 |
| KR20040101398A (ko) | 2004-12-02 |
| CN1658834A (zh) | 2005-08-24 |
| ZA200406910B (en) | 2006-06-28 |
| BR0309009A (pt) | 2005-03-22 |
| EP1494645A2 (en) | 2005-01-12 |
| MXPA04009605A (es) | 2005-01-11 |
| CA2479520A1 (en) | 2003-10-16 |
| WO2003084503A2 (en) | 2003-10-16 |
| JP2005528374A (ja) | 2005-09-22 |
| WO2003084503A3 (en) | 2004-04-08 |
| PL372963A1 (en) | 2005-08-08 |
| IL163737A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004133034A (ru) | Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38 | |
| RU2004132847A (ru) | Способ лечения гиперсекреции слизи | |
| JP2005529098A5 (enExample) | ||
| RU2001122111A (ru) | Ароматические гетероциклические соединения в качестве противовоспалительных агентов | |
| JP2002539198A5 (enExample) | ||
| KR102850550B1 (ko) | 트로포미오신 수용체 키나아제(trk) 분해 화합물 및 사용 방법 | |
| JP2003514808A5 (enExample) | ||
| AR034089A1 (es) | Ureas, un procedimiento para su preparacion, las composiciones farmaceuticas que las contienen, y el uso de estas ureas para preparar un medicamento para el tratamiento de enfermedades inflamatorias y autoinmunes | |
| US20170266192A1 (en) | Methods for improving diaphragm function | |
| CA2511970A1 (en) | Urea derivatives useful in the treatment of heart failure | |
| JP2024138500A (ja) | 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法 | |
| YU88491A (sh) | Amidi izoksazol-4-karboksilne kiseline i amidi hidroksialkiliden-cijanosirćetne kiseline i postupak za dobijanje farmaceutskih preparata koji sadrže ta jedinjenja | |
| JP2005528374A5 (enExample) | ||
| WO1998021183A1 (de) | Enantiomerenreine, basische aryl-cycloalkyl-hydroxycarbonsäureester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln | |
| CN110167933A (zh) | 作为αV整联蛋白抑制剂的唑酰胺和胺 | |
| DE01998348T1 (de) | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu ihrer herstellung sowie neue verfahren zur herstellung anderer formen | |
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| WO2010037081A1 (en) | Melanocortin receptor-specific spiro-piperidine compounds | |
| EP4186507A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| CA2449249A1 (en) | Nr2b receptor antagonists for the treatment or prevention of migraines | |
| EP1530477A1 (en) | COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| WO2023001028A1 (zh) | 杂芳-3-哌啶二酮类化合物及其应用 | |
| JP2019512459A (ja) | ７員環化合物、その調製方法、その医薬組成物、およびその使用 | |
| WO2009059030A1 (en) | Pyrazole derivatives as kinase inhibitors | |
| WO2024219446A1 (ja) | 環状ペプチド化合物及び界面活性剤を含む組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20071127 |